Travere Therapeutics
3611 Valley Centre Drive
Suite 300
San Diego
California
92130
United States
Tel: 888-969-7879
Website: https://travere.com/
About Travere Therapeutics
Even with the challenges all of us are facing as a result of COVID-19, Travere Therapeutics continues to come together as an organization to live our mission each day to support our patients and invest in our capabilities for the future. At the center of these efforts are our people. Travere remains committed to preventing interruption of our clinical programs, providing unwavering patient support and ensuring delivery of therapies to our patients. Moments like this are when our patients need us the most.
If you want to join a team that now more than ever lives its mission to the fullest extent, please review our current opportunities and apply to positions that may be of interest to you.
Travere is continuing to hire for all open roles with all interviewing and onboarding done virtually due to COVID-19.
Everyone new to the team, along with our current staff, will temporarily work from home until it is safe to return to our offices.
At Travere Therapeutics, formerly Retrophin, our number one priority will always be the patients we serve - they are “why” we come to work each day. Our Why is ingrained into our culture and is paramount to “what” we do every day and “how” we do it to achieve our mission of identifying, developing and delivering life-changing therapies to people living with rare disease. By working hard, supporting our team members and living our values of Accountability, Entrepreneurial Spirit, Integrity, Patient Focus, Scientific Excellence and Teamwork, we strive to help our organization succeed and pursue our vision - to become a preeminent, global and fully-integrated biopharmaceutical company within the rare disease community that is dedicated to giving patients a chance and providing hope.
Our pipeline features late-stage development programs targeting rare diseases with significant unmet medical needs including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. In partnership with leaders in patient advocacy and government research, we are also working to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, rare conditions with no approved treatment options. Our R&D efforts are supported by revenues from our four commercial products Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin) and THIOLA EC™ (tiopronin) delayed-release tablets.
Through our portfolio of approved products and promising pipeline focused on hepatology, nephrology and neurology, we strive to help people achieve the best possible outcomes today and tomorrow. But most importantly, it is the commitment of our experienced, knowledgeable and compassionate team members, who put patients at the center of everything they do, that truly matters.
312 articles about Travere Therapeutics
-
Travere Therapeutics Reports First Quarter 2023 Financial Results
5/4/2023
Travere Therapeutics, Inc. reported its first quarter 2023 financial results and provided a corporate update.
-
Despite the Phase III failure, Travere and partner CSL Vifor will explore potential regulatory paths for sparsentan as a treatment for focal segmental glomerulosclerosis. -
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
5/1/2023
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis (FSGS).
-
Travere Therapeutics to Report First Quarter 2023 Financial Results
4/26/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets.
-
Interim Analysis of the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Presented by Travere Therapeutics at NKF Spring Clinical Meetings
4/13/2023
The National Kidney Foundation (NKF) will feature a late-breaking plenary session by Travere Therapeutics on the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ (Sparsentan) in adults with IgA nephropathy (IgAN).
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 13, 2023
4/13/2023
Travere Therapeutics, Inc. announced that on April 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to five new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 30,000 shares of its common stock.
-
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
4/1/2023
Travere Therapeutics, Inc. announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT Study evaluating FILSPARI™ in adults with IgA nephropathy.
-
Travere Therapeutics to Present at Upcoming Investor Conferences - March 28, 2023
3/28/2023
Travere Therapeutics, Inc. announced that Company management will participate in the following upcoming conferences.
-
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
3/23/2023
Travere Therapeutics, Inc. announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating FILSPARI™ in IgA nephropathy will be presented in late-breaking trial sessions at both the ISN World Congress of Nephrology in Bangkok, Thailand, March 30-April 2, and NKF Spring Clinical Meetings in Austin, TX, April 11-15, 2023.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 14, 2023
3/14/2023
Travere Therapeutics, Inc. announced that on March 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to four new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 17,250 shares of its common stock.
-
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
3/14/2023
Travere Therapeutics, Inc. announced that the Company will present a quantitative systems pharmacology model for predicting the effects of the investigational enzyme replacement therapy pegtibatinase, in classical homocystinuria, as well as real-world evidence on the prevalence and potential underdiagnosis and/or underreporting of HCU in the United States, at the 2023 Society for Inherited Metabolic Disorders 44th Annual Meeting in Salt Lake City, UT, March 18-21, 2023.
-
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
3/3/2023
Travere Therapeutics, Inc. announced the completion of its previously announced underwritten public offering of 9,703,750 shares of its common stock at a price to the public of $21.00 per share and pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant, including 1,428,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.
-
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
3/1/2023
Travere Therapeutics, Inc. announced the pricing of an underwritten public offering of 8,275,000 shares of its common stock at a price to the public of $21.00 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant.
-
Travere Therapeutics Announces Proposed Public Offering of Common Stock - February 27, 2023
2/27/2023
Travere Therapeutics, Inc. announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175,000,000 of its common stock.
-
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
2/23/2023
Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2022 financial results and provided a corporate update.
-
The FDA granted accelerated approval Friday to Travere Therapeutics’ sparsentan, now to be marketed as Filspari, to reduce the burden of proteinuria in adults with primary IgA nephropathy. -
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
2/17/2023
Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. has received accelerated approval from the U.S. Food and Drug Administration for FILSPARI™ to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.
-
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
2/17/2023
Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval to FILSPARI™ to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.
-
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
2/16/2023
Travere Therapeutics, Inc. announced it will report fourth quarter and full year 2022 financial results on Thursday, February 23, 2023, after the close of the U.S. financial markets.
-
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 13, 2023
2/13/2023
Travere Therapeutics, Inc. announced that on February 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 17,700 shares of its common stock.